Biogen Inc (BIIB.OQ)
8 Dec 2017
* BIOGEN APPOINTS MARK HERNON AS SVP, CHIEF INFORMATION OFFICER Source text for Eikon: Further company coverage:
* SARISSA CAPITAL MANAGEMENT'S ALEXANDER DENNER REPORTS PURCHASE OF 30,000 SHARES OF BIOGEN INC'S COMMON STOCK BETWEEN NOV 28-29 - SEC FILING Source text: (http://bit.ly/2niyLpi) Further company coverage:
Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.
Nov 27 Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.
* Appoints Jeff Capello as executive vice president and chief financial officer
* Acorda announces royalty monetization transactions for $53 million
LONDON, Nov 13 Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease.
* Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab
Oct 25 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Wednesday a bigger jump than expected in quarterly core profit, raised its profit and sales guidance, and said it planned to boost operations in North America.
* Indexes up: Dow 0.7 pct, S&P 500 0.2 pct, Nasdaq 0.2 pct (Adds background in paragraph 8.)
|Johnson & Johnson (JNJ.N)||$140.59||--|
|Pfizer Inc. (PFE.N)||$35.74||--|
|Novartis AG (NOVN.S)||CHF82.90||-0.20|
|Merck & Co., Inc. (MRK.N)||$55.57||--|
|Roche Holding Ltd. (ROG.S)||CHF240.40||-0.10|
|Roche Holding Ltd. (RO.S)||CHF243.10||+0.60|
|Bayer AG (BAYGn.DE)||€104.95||+0.25|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€73.65||+0.47|
|GlaxoSmithKline plc (GSK.L)||1,301.50||+14.00|